公开(公告)号：US20240336908A1

公开(公告)日：2024-10-10

申请号：US18749788

申请日：2024-06-21

申请人： SHANGHAI BAO PHARMACEUTICALS CO., LTD.

发明人： Yanjun LIU ,  Zheng WANG ,  Zhen ZHU ,  Lin LU

IPC分类号： C12N9/52 ,  A61K38/48 ,  A61P37/06

CPC分类号： C12N9/52 ,  A61K38/48 ,  A61P37/06

摘要： Provided are a mutant of an immunoglobulin degrading enzyme IdeE, a protein comprising the mutant, and a use of a composition and a kit in preparation of a drug for reducing the level of IgG in a subject. The mutant has amino acid substitution, N-terminal truncated and/or C-terminal truncated on one or more of positions 8, 10, 24, 59, 97, and 280 of the amino acid sequence shown in SEQ ID NO: 2, and the mutant has the function of the immunoglobulin degrading enzyme IdeE, and has higher activity and thermal stability than wild-type IdeE.

公开(公告)号：US12102691B2

公开(公告)日：2024-10-01

申请号：US17350769

申请日：2021-06-17

申请人： Massachusetts Eye and Ear Infirmary ,  President and Fellows of Harvard College

发明人： Zheng-Yi Chen ,  David R. Liu ,  Margie Li ,  David B. Thompson ,  John Zuris

IPC分类号： A61K48/00 ,  A61K9/127 ,  A61K38/00 ,  A61K38/10 ,  A61K47/64 ,  A61K47/69 ,  C07J7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/46 ,  C07K14/47 ,  C07K19/00 ,  C12N5/0793 ,  C12N9/00 ,  C12N9/22 ,  C12N9/52 ,  C12N15/11 ,  C12N15/113 ,  C12N15/87 ,  C12N15/88 ,  C12N15/90

CPC分类号： A61K48/0008 ,  A61K9/1272 ,  A61K38/00 ,  A61K38/10 ,  A61K47/64 ,  A61K47/6911 ,  A61K48/0075 ,  A61K48/0083 ,  C07J7/009 ,  C07K7/06 ,  C07K7/08 ,  C07K14/463 ,  C07K14/47 ,  C07K19/00 ,  C12N5/062 ,  C12N9/00 ,  C12N9/22 ,  C12N9/52 ,  C12N15/11 ,  C12N15/113 ,  C12N15/87 ,  C12N15/88 ,  C12N15/907 ,  C12Y304/2207 ,  C07K2319/06 ,  C07K2319/21 ,  C07K2319/33 ,  C07K2319/60 ,  C12N2310/20 ,  C12N2310/3513 ,  C12N2510/00

摘要： Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

公开(公告)号：US20240277820A1

公开(公告)日：2024-08-22

申请号：US18418028

申请日：2024-01-19

申请人： AbbVie Inc.

发明人： Robert R. Kehrer ,  Jared Wiig ,  Hui Xiang ,  Phillip P. Nguyen ,  Hemant A. Patel ,  Connie J. Ng ,  Cortnie M. Guerrero

IPC分类号： A61K38/48 ,  C12N9/52

CPC分类号： A61K38/4893 ,  C12N9/52 ,  C12Y304/24069

摘要： Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT/A) complex comprising a 150 kDa BoNT/A. Said 150 kDa BoNT/A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT/A sequence variant species with a C-terminal truncated light chain.

公开(公告)号：US20240254170A1

公开(公告)日：2024-08-01

申请号：US18594957

申请日：2024-03-04

申请人： AgroSpheres, Inc.

发明人： Ameer Hamza SHAKEEL ,  Sepehr ZOMORODI ,  Joseph Thomas FRANK ,  Zachery George DAVIS ,  Payam POURTAHERI

IPC分类号： C07K14/195 ,  A01N25/28 ,  A01N63/22 ,  A01N63/50 ,  C07K14/32 ,  C07K14/335 ,  C07K14/34 ,  C12N1/08 ,  C12N9/52 ,  C12N9/54 ,  C12N15/62 ,  A61K39/108 ,  B01F101/04

CPC分类号： C07K14/195 ,  A01N25/28 ,  A01N63/22 ,  A01N63/50 ,  C07K14/32 ,  C07K14/335 ,  C07K14/34 ,  C12N1/08 ,  C12N9/52 ,  C12N9/54 ,  C12N15/62 ,  A61K39/0258 ,  B01F2101/04 ,  C07K2319/705

摘要： The present disclosure is generally directed to an anucleated cell-based platforms for encapsulation and delivery of agricultural compounds. Disclosed herein are compositions for the stable and targeted delivery of agricultural compounds within achromosomal and/or anucleated cells. The present disclosure also provides methods of improving encapsulation and retention of agricultural compounds in achromosomal and/or anucleated cells.

公开(公告)号：US20240252553A1

公开(公告)日：2024-08-01

申请号：US18578856

申请日：2022-07-12

申请人： VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.

发明人： Bahareh BEHKAM ,  Eric LEAMAN

IPC分类号： A61K35/74 ,  A61K45/06 ,  A61P35/00 ,  C12N9/52 ,  C12N15/74

CPC分类号： A61K35/74 ,  A61K45/06 ,  A61P35/00 ,  C12N9/52 ,  C12N15/74 ,  C12Y304/24003

摘要： Cancer is a significant cause of mortality and morbidity worldwide. One of the principal impediments to the broad success of conventional chemotherapy is poor delivery to and transport within the tumor microenvironment (TME), caused by irregular and leaky vasculature, the lack of functional lymphatics, and underscored by the overproduction of extracellular matrix (ECM) proteins such as collagen. Described herein are engineered Salmonella Typhimurium (S. Typhimurium) bacteria and uses thereof. In some embodiments, the engineered S. Typhimurium bacteria comprises an exogenous collagenase. Also described in exemplary embodiments herein methods of using the engineered S. Typhimurium bacteria, such as part of a,cancer therapy.

公开(公告)号：US12049653B2

公开(公告)日：2024-07-30

申请号：US17480166

申请日：2021-09-21

申请人： Trustees of Dartmouth College

发明人： Karl E. Griswold ,  Hongliang Zhao

IPC分类号： C12N9/52 ,  A61K38/00

CPC分类号： C12N9/52 ,  C12Y304/24075 ,  A61K38/00

摘要： Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

公开(公告)号：US20240245760A1

公开(公告)日：2024-07-25

申请号：US18418068

申请日：2024-01-19

申请人： AbbVie Inc.

发明人： Robert R. Kehrer ,  Jared Wiig ,  Hui Xiang ,  Phillip P. Nguyen ,  Hemant A. Patel ,  Connie J. Ng ,  Cortnie M. Guerrero

IPC分类号： A61K38/48 ,  C12N9/52

CPC分类号： A61K38/4893 ,  C12N9/52 ,  C12Y304/24069

摘要： The present disclosure relates to Clostridium botulinum neurotoxin serotype A (BoNT/A) compositions with a plurality of 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT/A) complex species. Provided herein are compositions comprising BoNT/A that have a low level of oxidation at specific methionine positions of 150 kDa BoNT/A. Further provided herein are methods of producing a composition comprising BoNT/A using a low temperature during the process of fermenting Clostridium botulinum bacteria.

公开(公告)号：US20240240151A1

公开(公告)日：2024-07-18

申请号：US18448864

申请日：2023-08-11

申请人： OSSIUM HEALTH, INC.

发明人： Erik J. WOODS ,  Brian H. JOHNSTONE ,  Dongsheng GU ,  Hannah Marie MILLER

IPC分类号： C12N5/0775 ,  C12N9/52

CPC分类号： C12N5/0663 ,  C12N9/52 ,  C12N2509/00

摘要： Compositions and methods for the extraction mesenchymal cells from deceased donor bone, and therapeutic applications thereof, along with combination therapeutic applications comprising mesenchymal cells from deceased donors and bone marrow derived from deceased donors are presented.

公开(公告)号：US20240207376A1

公开(公告)日：2024-06-27

申请号：US18513879

申请日：2023-11-20

申请人： UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

发明人： Justin SIEGEL ,  David BAKER ,  Sydney Rin Anna GORDON ,  Ingrid Swanson PULTZ ,  Elizabeth Joy STANLEY ,  Sarah Jane WOLF

IPC分类号： A61K38/48 ,  C12N9/52

CPC分类号： A61K38/482 ,  A61K38/48 ,  C12N9/52 ,  C12Y304/21

摘要： The invention provides compositions and methods for treating celiac sprue.

公开(公告)号：US11993794B2

公开(公告)日：2024-05-28

申请号：US17203473

申请日：2021-03-16

申请人： Fred Hutchinson Cancer Center

发明人： Rupesh Amin

IPC分类号： C12N9/52 ,  C07K14/705 ,  C07K16/00 ,  C07K16/44 ,  C07K16/46 ,  C12N9/50 ,  C12N9/64 ,  C12N9/96 ,  C12N15/70 ,  C12N15/81

CPC分类号： C12N9/52 ,  C07K14/705 ,  C07K16/005 ,  C07K16/44 ,  C07K16/468 ,  C12N9/50 ,  C12N9/6472 ,  C12N9/96 ,  C07K2317/22 ,  C07K2317/32 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/61 ,  C07K2319/70 ,  C07K2319/71 ,  C07K2319/715 ,  C07K2319/80 ,  C12N15/70 ,  C12N15/81

摘要： Methods to create chemically-induced dimerizing (CID) protein systems and uses thereof are described. The methods utilize antibody binding domain dimerizing proteins. The created systems can be used to regulate cellular events such as gene expression, receptor signaling and cell death to effectuate a variety of clinically relevant treatment outcomes.